March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
March 20th 2023
Radiosurgery uses stereotactic targeting methods to precisely deliver highly focused, large doses of radiation to small intracranial tumors and arteriovenous malformations (AVMs). This article reviews the most common
Medical Treatment for Intractable Obesity in Pediatric Cancer PatientsJuly 1st 1998
A potential treatment for hypothalamic obesity that often afflicts children who receive treatment for brain tumors or leukemia has been discovered by researchers at St. Jude Children’s Research Hospital. Many of these childhood cancer survivors die in
UT Southwestern Researchers Test New Radiation Therapy Device for Brain CancerMay 1st 1998
Doctors at UT Southwestern Medical Center at Dallas and Zale Lipshy University Hospital are using an experimental radiation therapy device to treat brain cancer patients for whom conventional radiation treatments have not been effective.
Herpes Simplex Virus Investigated for Treatment of Brain TumorsMay 1st 1998
The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center announced a new phase I clinical trial recently to investigate a genetically re-engineered herpes simplex virus as a treatment of malignant brain tumors.
Traditionally, cytotoxic drugs have played a limited role in the treatment of brain tumors, but important advances in chemotherapy have occurred during the past decade. Certain central nervous system (CNS) malignancies are
Carmustine Wafer to Be Studied in Newly Diagnosed Malignant GliomaFebruary 1st 1998
Rhone-Poulenc Rorer recently announced the start of a phase III clinical trial of its prolifeprosan with carmustine implant (Gliadel Wafer), in conjunction with surgery and radiation, in patients newly diagnosed with malignant glioma. The purpose of this study is to confirm the results of an earlier, small phase III trial showing that the carmustine wafer offers a significant survival advantage over placebo when used with initial surgery for malignant glioma.
Radiosurgery Offers Alternative to Open Surgery for Patients With Brain TumorsJanuary 1st 1998
There is certainly no good place to get a brain tumor, but one of the worst is in the lower portion of the brain along the base of the skull. Skull-base tumors are often intimately entwined with critical arteries and cranial nerves that emerge from the base of the brain, making surgical removal challenging and risky.
Oligodendroglial Component in Anaplastic Astrocytomas: A Prognostic Factor for SurvivalAugust 1st 1997
Perhaps contrary to expectations, the presence of an oligodendroglial component in patients with anaplastic astrocytomas was associated with a significantly longer survival than were pure anaplastic tumors. This finding emerged from a randomized
An Overview of Radiotherapy Trials for the Treatment of Brain MetastasesNovember 1st 1995
A review of the English literature was undertaken to (1) determine the efficacy of radiation therapy for the treatment of brain metastases, (2) identify prognostic factors, and (3) ascertain whether there is an effect of treatment technique on outcome. Critical analysis of relevant randomized trials indicated that radiation therapy can effectively palliate the symptoms of brain metastases.
Current Management of MeningiomasJanuary 1st 1995
Although generally benign tumors, meningiomas can cause serious neurological injury and, at times, vexatious management difficulties. Currently, the accepted management of these tumors is attempted total surgical excision when technically possible and associated with an acceptable risk. However, even with innovations in instrumentation and refinements in surgical technique, the goal of total resection may not be achievable. For these patients, and for those with recurrent tumors, options for treatment include reoperation, radiation therapy, and chemotherapy. Recent developments in surgical technique and instrumentation, radiosurgery, and brachytherapy have increased the treatment options, while clinical trials with tamoxifen and mifepristone (RU486) are adding information on the effectiveness of these drugs as chemotherapeutic agents. While the search continues for a uniformly successful management plan, physicians must be aware of the available options and try to help the patient decide which treatment is appropriate, based on current medical knowledge. [ONCOLOGY 9(1):83-100]
Commentary (Fick/Gutin): Current Management of MeningiomasJanuary 1st 1995
Surgical resection has been the preferred treatment for meningiomas since the era of the pioneering neurosurgeon, Harvey Cushing. The great majority of these tumors are histologically benign, circumscribed lesions that grow slowly and tend to compress and displace, rather than invade, the surrounding intracranial structures. In contrast to the intrinsic brain tumors of glial origin, most meningiomas have well-defined borders, enabling the surgeon to dissect the tumor capsule from the arachnoid lining of the adjacent brain, blood vessels, and cranial nerves. Consequently, complete removal can be accomplished without needing to sacrifice functional tissue. In these cases, surgery is often curative, and associated with the preservation of, if not improvements in, the neurological condition.